Ispire Technology Inc【ISPR】株式ニュース

Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2026May 7, 2026 7:00 AM
PR Newswire (US) Cash Increased Sequentially by $468,000 to $18 MillionPlans to Achieve Cash Flow Positive in Second Half of Calendar Year 2026 Business Stabilized Following Strategic RepositioningPhased Roadmap Targets Billions in Addressable Market, Including ~$73B Global Vape, ~$50–70B U.S. Flavored Vape, and $24B+ Global G-Mesh Glass TechnologyLOS ANGELES, May 7, 2026 /PRNewswire/ -- Ispire Technology Inc. (Nasdaq: ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2026, for the three months ended March 31, 2026. Michael Wang, Co-Chief Executive Officer of Ispire, commented, "This quarter reflects the successful stabilization of our business and with cash growing sequentially by $468,000 to $18 million, we are now executing against a phased roadmap, with near-term revenue drivers already in production and transformative technology opportunities on the horizon:Our Malaysia manufacturing is live today, giving us a 25% tariff advantage over China in a ~$73B global vape market.Supply of nicotine pouches to global customers commenced in April 2026.Vapor ODM launches in July 2026 for mid-sized brands, with large brand partnerships targeted for 2027.Looking further ahead (2027 and beyond):Age-gating technology through IKE Tech has the potential to unlock the ~$50–70B US flavored vape marketG-Mesh glass technology is already drawing interest from big tobacco in a $24B+ legal global market."With cash generation this quarter and proprietary technologies in age-gating and G-Mesh that no competitor can replicate, we have multiple shots on goal across billion-dollar markets, and we believe Ispire is uniquely positioned to deliver outsized value for shareholders."Multiple Growth Catalysts, Each Backed by a Massive Addressable MarketCatalystTimelineOpportunityMalaysia
ManufacturingNow~$73B global vape market; 25% tariff advantage over
ChinaVapor ODMJuly 2026 /
2027Mid-sized brands in 2026; large brand partnerships in
2027Age-Gating (IKE
Tech)2027+~$50-70B US flavored vape market currently locked;
~6B devices/year US TAMG-Mesh Technology2027+$24B+ legal global vape market; licensing discussions
with big tobacco underwayFinancial Results for the Fiscal Third Quarter Ended March 31, 2026Revenue was $18.7 million, compared to $26.2 million in the third quarter of fiscal 2025 and $20.3 million in the prior sequential quarter. The sequential decline of $1.6 million, or 8%, represents the smallest second-to-third quarter decline in the Company's history, reflecting the typical seasonal impact of Chinese New Year-related factory shutdowns. The year-over-year decline reflects the Company's continued strategic shift away from lower-quality cannabis revenue toward regulated nicotine delivery and compliance technologies. Overall, the business continues to stabilize.Gross profit of $2.0 million compared to $4.8 million for the third quarter of fiscal 2025 and $3.5 million in the prior sequential quarter. Gross margin was impacted by approximately $2.2 million in one-time product returns from legacy cannabis customers with whom the Company has ceased doing business. Gross margin of 10.7% compared to 18.2% for the third quarter of fiscal 2025, is primarily attributable to the approximately $2.2 million one-time product returns from legacy cannabis customers with whom the Company has ceased doing business.Total operating expenses excluding bad debt expense of $5.9 million, a 36% reduction when compared to operating expenses of $9.3 million for the third quarter of fiscal 2025, and a 3.7% reduction when compared to operating expenses of $6.1 million in the prior sequential quarter. Bad debt expense was $5.6 million, which is $0.5 million less than the third quarter of fiscal 2025 and $1.4 million more than the prior quarter.Net loss of $9.5 million or ($0.17) per share, a 12.3% decrease, compared to net loss of $10.9 million, or ($0.19) per share, in the third quarter of fiscal 2025, and a 44.4% increase compared a net loss of $6.6 million in the prior sequential quarter.Cash: At March 31, 2026, the Company held cash of $18.0 million and working capital of $0.9 million.Conference CallThe Company will conduct a conference call at 8 am ET on Friday, May 7, 2026, to discuss the results, followed by a Q&A session.To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call."Date: Thursday, May 7, 2026Time: 8:00 am ET Dial-In Numbers: United States 844-826-3033 or International + 1-412-317-5185This conference call will be webcast live and can be accessed by all interested parties at  https://viavid.webcasts.com/starthere.jsp?ei=1761477&tp_key=3958311007Please access the link at least fifteen minutes prior to the start of the call to register, download, and install any necessary audio software.A playback will be available until 11:59 pm ET on Friday, May 21, 2026. To listen, please dial 1-844-512-2921 or 1-412-317-6671. Use the passcode 10208863 to access the replay.About Ispire Technology Inc.Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company's operating subsidiaries own or license more than 400 patents worldwide. Ispire's branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People's Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company's cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information visit www.ispiretechnology.com or follow Inspire on Instagram, LinkedIn, Twitter and YouTube.Forward Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company's joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the "Joint Venture") may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture's ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company's ability to collect its accounts receivable in a timely manner; the Company's business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™'s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Cautionary Note on Forward-Looking Statements" and the additional risk described in Ispire's Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.Contact:HAYDEN IR:
James Carbonara
(646)-755-7412
james @Sam_0
brett@haydenir.com-- Tables Follow – ISPIRE TECHNOLOGY INC.UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS(In $USD, except share and per share data)

March 31,
2026

June 30,
2025
Assets

Current assets:

Cash
$18,033,652

$24,351,765
Restricted cash

50,000

-
Accounts receivable, net

28,651,558

39,664,145
Inventories

5,480,044

6,647,970
Prepaid expenses and other current assets

3,523,741

2,244,505
Total current assets

55,738,995

72,908,385
Non-current assets:

Accounts receivable, net of current portion

-

7,367,158
Property, plant and equipment, net

2,665,534

2,952,800
Intangible assets, net

2,601,408

2,232,620
Right-of-use assets – operating leases

3,855,373

5,030,005
Other investment

2,000,000

2,000,000
Equity method investment

8,839,130

9,515,546
Other non-current assets

210,617

210,617
Total non-current assets

20,172,062

29,308,746
Total assets
$75,911,057

$102,217,131
Liabilities and stockholders' (deficit)/equity

Current liabilities

Accounts payable
$5,005,033

$4,172,476
Accounts payable – related party

38,159,288

52,420,256
Contract liabilities

3,043,470

4,861,250
Accrued liabilities and other payables

6,003,509

8,099,991
Borrowing – current portion

1,092,052

1,146,766
Operating lease liabilities – current portion

1,546,770

1,838,815
Total current liabilities

54,850,122

72,539,554

Non-current liabilities:

Amount due to a related party

35,000,000

25,000,000
Borrowing – net of current portion

-

805,361
Operating lease liabilities – net of current portion

2,265,347

3,267,522
Total non-current liabilities

37,265,347

29,072,883
Total liabilities

92,115,469

101,612,437

Commitments and contingencies

Stockholders' (deficit)/equity:

Common stock, par value $0.0001 per share; 140,000,000 shares authorized;
57,399,396 and 57,193,734 shares issued and outstanding as of March 31, 2026
and June 30, 2025

5,740

5,719
Treasury stock, at cost

(60,488)

(60,488)
Additional paid-in capital

51,541,046

48,833,601
Accumulated deficit

(67,450,024)

(48,065,267)
Accumulated other comprehensive loss

(240,686)

(108,871)
Total stockholders' (deficit)/equity

(16,204,412)

604,694
Total liabilities and stockholders' (deficit)/equity
$75,911,057

$102,217,131
ISPIRE TECHNOLOGY INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE LOSS(In $USD, except share and per share data)

Three Months Ended
March 31,

Nine Months Ended
March 31,

2026

2025

2026

2025

Revenue
$18,685,501

$26,190,725

$69,322,941

$107,356,898

Cost of revenue

16,694,576

21,414,820

58,710,643

87,184,044

Gross profit

1,990,925

4,775,905

10,612,298

20,172,854

Operating expenses:

Sales and marketing expenses

1,091,907

1,656,527

4,133,079

6,710,438
Credit loss expenses

5,564,497

6,103,688

11,537,950

13,389,767
General and administrative expenses

4,818,256

7,601,131

13,995,180

23,281,014

Total Operating expenses

11,474,660

15,361,346

29,666,209

43,381,219

Loss from operations

(9,483,735)

(10,585,441)

(19,053,911)

(23,208,365)

Other income (expense):

Interest income

52,971

3,480

253,365

63,321
Interest expense

(87,215)

(35,646)

(299,582)

(60,183)
Exchange (loss) gain, net

(30,294)

24,341

269,745

(103,247)
Other income (expense), net

202,697

(86,239)

215,688

(47,906)

Total Other income (expense), net

138,159

(94,064)

439,216

(148,015)

Loss before income taxes

(9,345,576)

(10,679,505)

(18,614,695)

(23,356,380)

Income taxes

(177,407)

(176,990)

(770,062)

(1,093,774)

Net loss
$(9,522,983)

$(10,856,495)

$(19,384,757)

$(24,450,154)

Other comprehensive loss

Foreign currency translation adjustments

(10,490)

(2,860)

(131,815)

(84,327)
Comprehensive loss
$(9,533,473)

$(10,859,355)

$(19,516,572)

$(24,534,481)

Net loss per share

Basic and diluted
$(0.17)

$(0.19)

$(0.34)

$(0.43)

Weighted average shares outstanding:

Basic and diluted

57,293,826

57,003,488

57,269,726

56,752,454
ISPIRE TECHNOLOGY INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In $USD, except share and per share data)

Nine Months Ended
March 31,

2026

2025

Net loss
$(19,384,757)

$(24,450,154)
Adjustments to reconcile net loss to net cash (used in)/provided by operating activities:

Depreciation and amortization

691,894

592,280
Credit loss expenses

11,537,950

13,389,767
Right-of-use assets amortization

1,172,118

1,001,101
Stock-based compensation expenses

2,752,467

4,923,751
Inventory impairment

2,386,751

73,692
Loss from equity method investment

676,416

407,028
Debt issuance cost amortization

96,937

-
Changes in operating assets and liabilities:

Accounts receivable

6,841,795

(14,080,837)
Inventories

(1,218,825)

(1,485,433)
Prepaid expenses and other current assets

(1,332,448)

(715,969)
Accounts payable and accounts payable – related party

(3,428,411)

10,962,439
Contract liabilities

(1,817,780)

(756,872)
Accrued liabilities and other payables

(876,774)

(969,068)
Operating lease liabilities

(1,291,706)

(961,244)
Net cash used in operating activities

(3,194,373)

(12,069,519)

Cash flows from investing activities:

Purchase of property, plant and equipment

(324,225)

(140,956)
Capitalized costs for patents

(449,191)

(781,254)
Investment in joint venture

(1,298,311)

(767,285)
Net cash used in investing activities

(2,071,727)

(1,689,495)

Cash flows from financing activities:

Common stock repurchase

(45,001)

(60,488)
Proceeds from long term debt

-

2,339,362
Repayment of borrowing

(957,012)

-
Net cash (used in)/provided by financing activities

(1,002,013)

2,278,874

Net decrease in cash

(6,268,113)

(11,480,140)
Cash – beginning of period

24,351,765

35,071,294
Cash and restricted cash– end of period
$18,083,652

$23,591,154
Reconciliation of cash and restricted cash

Cash

18,033,652

23,518,560
Restricted cash

50,000

72,594
Total cash and restricted cash
$18,083,652

$23,591,154
Supplemental non-cash investing and financing activities

Reclassification of accounts receivable – noncurrent to accounts receivable
$6,934,364

$-
Reclassification of accounts payable – related party to amount due to a related party
$10,000,000

$-
Leased assets obtained in exchange for operating lease liabilities
$-

$2,771,082
Unpaid long term investment in accrued liabilities and other payables
$-

$8,232,715
Supplemental disclosures

Cash paid for income taxes
$1,614,273

$1,413,533
Cash paid for interest
$299,582

$60,183
ISPIRE TECHNOLOGY INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In $USD, except share and per share data)

Three Months Ended
March 31,
2026

2025Net loss$     (9,522,983)

$       (10,856,495)Adjustments to reconcile net loss to net cash -used in/provided by operating
activities:$                       -

$                           -Depreciation and amortization$           210,652

$               198,955Credit loss expenses$        5,564,497

$            6,103,688Right-of-use assets amortization$           479,982

$               371,717Stock-based compensation expenses$           992,478

$            1,470,877Inventory impairment$           849,313

$                          -Loss from equity method investment$           290,083

$               230,360Debt issuance cost amortization$             32,312

$                          -Changes in operating assets and liabilities:$                      -

$                           -Accounts receivable$        3,662,298

$            1,170,940Inventories$     (1,291,943)

$               181,075Prepaid expenses and other current assets$        (363,641)

$               139,686Accounts payable and accounts payable – related party$        3,582,462

$         (9,743,313)Contract liabilities$     (1,927,665)

$            (549,992)Accrued liabilities and other payables$          (99,500)

$            (838,174)Operating lease liabilities$        (489,737)

$            (376,953)Income tax payable$          (12,590)

$                           -Net cash provided by operating activities$        1,956,018

$       (12,497,629)
$                      -

Cash flows from investing activities:$                      -

Purchase of property, plant and equipment$        (247,347)

$               181,808Capitalized costs for patents$        (156,349)

$                          -Investment in joint venture $        (765,000)

$            (767,285)Net cash used in investing activities$     (1,168,696)

$            (585,477)
$                      -

Cash flows from financing activities:$                      -

Common stock repurchase $                      -

$              (60,488)Proceeds from long term debt$                      -

$            2,339,362Repayment of borrowing$        (319,004)

$                           -Net cash used in financing activities$        (319,004)

$            2,278,874
$                       -

Net increase in cash$           468,318

$       (10,804,232)Cash – beginning of period$      17,615,334

$          34,395,386Cash and restricted cash– end of period$      18,083,652

$          23,591,154Reconciliation of cash and restricted cash

Cash$      18,033,652

$          23,518,560Restricted cash$             50,000

$                 72,594Total cash and restricted cash$      18,083,652

$          23,591,154Supplemental non-cash investing and financing activities

Reclassification of accounts receivable – noncurrent to accounts receivable$                      -

$                          -Reclassification of accounts payable – related party to amount due to a
related party$        6,000,000

$                          -Leased assets obtained in exchange for operating lease liabilities$                      -

$            2,771,082Unpaid long term investment in accrued liabilities and other payables$                      -

$            8,232,715Supplemental disclosures$                      -

$                          -Cash paid for income taxes $                  3,081    -

$                           -Cash paid for interest$             87,215

$                 35,646 View original content to download multimedia:https://www.prnewswire.com/news-releases/ispire-technology-inc-reports-financial-results-for-fiscal-third-quarter-2026-302764809.htmlSOURCE Ispire Technology Inc. Original: Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2026

Ispire Highlights Economic Impact of New FDA Guidance on Flavored ENDS Unlocking a $50 Billion Market and Driving Significant Potential Asset ValueMarch 16, 2026 8:00 AM
PR Newswire (US)

FDA establishes first-ever framework for flavored ENDS, recognizing device level age verification as a regulatory requirementFDA guidance unlocks an estimated $50 billion total addressable market, allowing companies to lawfully transition the 70% illicit flavored vape market into a compliant ecosystemIspire's 40%-owned IKE Tech joint venture is positioned to generate $5 million to $20 million in annual recurring SaaS revenue per customer in the USBased on conservative SaaS metrics, even a limited number of customers could potentially value the IKE joint venture in the hundreds of millions, dramatically increasing Ispire's book valueIspire-backed IKE Tech was first to file component PMTA for continuous, blockchain-enabled age-gating technologyLOS ANGELES, March 16, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, today highlighted the massive economic value and multi-billion-dollar market opportunity created for its shareholders by the U.S. Food and Drug Administration's (FDA) newly issued draft guidance outlining evidentiary expectations for Premarket Tobacco Product Applications (PMTAs) for flavored electronic nicotine delivery systems (ENDS).

The FDA's guidance effectively unlocks a $50 billion total addressable market by providing a lawful pathway for flavored vapes, which currently consist largely of illicit products. Ispire's 40%-owned joint venture, IKE Tech LLC ("IKE Tech" or "IKE"), is uniquely positioned to capture this market. IKE's recurring SaaS revenue model is expected to generate $5 million to $20 million annually per customer. Management believes that securing even a limited number of customers could value the IKE joint venture in the hundreds of millions, creating a highly valuable asset on Ispire's balance sheet.The guidance marks the first time the FDA has formally outlined a framework for evaluating flavored ENDS products, recognizing that device-level access technologies — or Device Access Restrictions (DAR) — may factor into whether a product meets the "appropriate for the protection of public health" (APPH) standard for PMTA authorization.The draft guidance highlights DAR technologies such as biometric authentication, geofencing, and continuous age verification as potential safeguards designed to prevent underage use of ENDS devices. FDA also emphasizes that traditional safeguards such as local age restrictions and point-of-sale verification that do not directly prevent youth use may not, when employed alone, sufficiently reduce youth use."We believe this guidance represents a major step toward a technology-enabled regulatory framework for the vapor category," said Michael Wang, Co-Chief Executive Officer of Ispire. "FDA's recognition of Device Access Restrictions validates our long-held position that continuous, device-level age verification can protect youth while preserving adult choice."Ispire has long advocated for technology-driven youth prevention solutions. Through IKE, a joint venture that includes Ispire as a founding partner, the Company has supported the development of advanced identity and authentication systems designed to control device access directly at the point of use, rather than solely at the point of sale.In 2025, IKE Tech submitted the first-ever component PMTA for a standalone, interoperable age-verification technology designed for integration across ENDS devices. The platform combines Bluetooth Low Energy (BLE) chips, biometric authentication, and blockchain-secured identity verification to ensure that only verified adult users can activate a device. In a multi-center Human Factors Validation Study submitted with the PMTA, the IKE age-gating technology achieved:100% effectiveness in preventing device activation by underage users100% accuracy in demographic verificationUser error rates below 1%, underscoring ease of use for adults91% user satisfaction with app simplicity and functionalityIn addition to age verification, the IKE technology platform can also support product authentication and anti-counterfeiting capabilities, helping manufacturers and regulators identify illicit or counterfeit devices that bypass regulatory safeguards, evade taxes, and undermine consumer safety.Economic Opportunity and Market Impact
The FDA's draft guidance may immediately unlock access to a multi-billion-dollar segment of the U.S. vapor market. With flavored products representing a substantial portion of consumer demand, the agency's recognition of DAR creates a potential pathway for compliant manufacturers to compete in segments previously dominated by illicit trade.Industry estimates suggest that approximately 70% of the current U.S. vape market consists of illicit or unauthorized products. Data suggests that the total U.S. vapor market is currently around $50 billion annually, when accounting for hard-to-track illicit and unauthorized products. IKE's technological solutions will allow companies to address this massive total market.Over recent months, IKE Tech is actively working with large tobacco companies, leading independent brands, and several of the largest e-cigarette manufacturers to evaluate integration of its technology into flavored PMTA submissions, while also receiving strong inbound interest from manufacturers seeking to bring compliant flavored ENDS products to the U.S. market.Following the FDA's guidance, Ispire believes this framework could also influence global regulatory policy, with several major markets potentially moving toward mandating device-level age verification for ENDS products.IKE's business model is structured as a recurring compliance technology platform, generating SaaS revenue from manufacturers integrating the system into their devices. Each customer using the technology is expected to generate approximately $5 million – $20 million in annual recurring SaaS revenue, alongside recurring per-device hardware sales or firmware licensing fees. Even a limited number of authorized flavored ENDS products incorporating IKE's technology could create significant enterprise value for the platform. About IKE Tech LLC
IKE Tech LLC is a joint venture comprised of Ispire Technology Inc., Touch Point Worldwide Inc. d/b/a Berify, and Chemular Inc. Founded in 2024, IKE Tech is building the identity layer for the physical world. With patented technologies spanning blockchain authentication, secure BLE communication, and AI-enhanced access control, IKE powers secure, user-centric device interactions across regulated and high-risk sectors.IKE's System-on-a-Chip allows manufacturers to embed customizable, interoperable access controls into vapor devices — ensuring authorized adult use and preventing youth access through real-time mobile and biometric authentication. Visit www.iketech.com.About Ispire Technology Inc.
Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company's operating subsidiaries own or license more than 400 patents worldwide. Ispire's branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People's Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company's cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company's joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the "Joint Venture") may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture's ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company's ability to collect its accounts receivable in a timely manner; the Company's business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™'s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Cautionary Note on Forward-Looking Statements" and the additional risk described in Ispire's Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.IR Contact:
Phil Carlson
+1-212-896-1233
ispire @anyany-209-2947
ispire@kcsa.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ispire-highlights-economic-impact-of-new-fda-guidance-on-flavored-ends-unlocking-a-50-billion-market-and-driving-significant-potential-asset-value-302714232.htmlSOURCE Ispire Technology Inc.

Original: Ispire Highlights Economic Impact of New FDA Guidance on Flavored ENDS Unlocking a $50 Billion Market and Driving Significant Potential Asset Value